Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

Hortobagyi, Gabriel N., Stemmer, Salomon M., Burris, Howard A., Yap, Yoon-Sim, Sonke, Gabe S., Hart, Lowell, Campone, Mario, Petrakova, Katarina, Winer, Eric P., Janni, Wolfgang, Conte, Pierfranco, Cameron, David A., André, Fabrice, Arteaga, Carlos L., Zarate, Juan P., Chakravartty, Arunava, Taran, Tetiana, Le Gac, Fabienne, Serra, Paolo, O’Shaughnessy, Joyce·2022·New England Journal of Medicine

DOI 10.1056/nejmoa2114663

Cited by (760)

Items 301–400 of 760

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
Jialin Zhang, Xinyu Xu, Yeyue Zhou, Jingyang Su, Jue Wang · 2025 · Frontiers in Oncology
New treatment options for hormone receptor positive breast cancer in 2023
Diana Lüftner · 2022 · Current Opinion in Obstetrics & Gynecology
Targeting Protein-Protein Interactions to Inhibit Cyclin-Dependent Kinases
Mark Alan Klein · 2023 · Pharmaceuticals
Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis
Elsa Curtit, Martine Marie Bellanger, Virginie Nerich, Delphine Héquet, Jean‐Sébastien Frenel, Olivier Cristeau, Roman Rouzier · 2023 · Frontiers in Oncology
Sexual Dysfunction in Patients With Metastatic Breast Cancer
Nusrat Jahan, Elizabeth Jane Cathcart-Rake, Robert Alan Vierkant, Nicole L. Larson, Charles L. Loprinzi, Ciara Catherine O'Sullivan, Stephanie S. Faubion, Carol L. Kuhle, Jennifer A. Vencill, Fergus J. Couch et al. · 2023 · Clinical Breast Cancer
Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy
Jenna Schlefman, Christiana M. Brenin, Trish Ann Millard, Patrick Michael Dillon · 2023 · Medical Oncology
Predicting drug–drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forward planning
Abha Kulkarni, Jasmeet Chadha Singh · 2024 · Expert Opinion on Drug Metabolism & Toxicology
Initial ribociclib plus endocrine therapy for HR +/ HER2 − advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study
Zhi-Min Shao, Zhongsheng Tong, Qiang Liu, Wei Li, Li Cai, Kunwei Shen, Huiping Li, Chuan Wang, Jin Yang, Zhenchuan Song et al. · 2024 · Cancer Medicine
Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer – efficacy, tolerability and quality of life results from the phase II METRO trial
Karolina Fs Larsson, Jamila Adra, Leif Klint · 2024 · The Breast
Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?
Silvia Brugiapaglia, Ferdinando Spagnolo, Simona Intonti, Francesco Novelli, Claudia Curcio · 2024 · Cells
An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial
Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng et al. · 2025 · 癌症：英文版
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report
Federica Miglietta, Maria Grazia Razeti, Aldo Caltavituro, Arianna Dri, Carmine Valenza, Giampaolo Bianchini, Laura Biganzoli, Andrea Botticelli, Michele Caruso, Saverio Cinieri et al. · 2025 · Critical Reviews in Oncology/Hematology
Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer
Diana Lüftner, Michael Patrick Lux, Tanja Natascha Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter Andreas Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel et al. · 2023 · Geburtshilfe und Frauenheilkunde
NAMS task force report on breast cancer in India
Sudeep Gupta, Atul Batra, Shankar Prinja, Hemant Malhotra, T. Mohanapriya, Shaji Thomas, Sanjoy Chatterjee, Tanuja Shet, Sanjay Prayagraj Thulkar, Beela Sarah Mathew · 2025 · Annals of the National Academy of Medical Sciences (India)
First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data
Mehmet Cem Fidan, Ahmet Emin Öztürk, Okan Aydın, Goncagül Akdağ, Ezgi Türkoğlu, Rumeysa Çolak, Nargız Majidova, Tanju Kapağan, Murad Guliyev, Emir Çelik et al. · 2025 · Journal of Clinical Medicine
Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis
Xiaojian Wang, Chenchen Li, Chenchen Li, Mengtian Qin, Jianyu Wu, Yuechen Qin, Yue Zou, Haijian Zeng, Chunlan Li, Xiaomeng Huang et al. · 2025 · Frontiers in Pharmacology
mTOR-driven autophagy suppression defines metabolic vulnerability in CDK4/6 inhibitor-resistant HR+/HER2− breast cancer
Luise von Wichert, Alina Stroh, Marie Witt, Michael Wanzel, Marco Mernberger, Sebastian Griewing, Thomas Wündisch, Berit Maria Pfitzner, Julia Teply‐Szymanski, Anne‐Sophie Litmeyer et al. · 2026 · Cell Death and Disease
Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer
Bülent Çetin, Dilek Erdem, İrem Karaman, Özge Gümüşay · 2026 · Current Treatment Options in Oncology
Continuation of CDK4/6 Inhibition and Switching of Hormonal Therapy After Progression on Prior CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis
Allan Ramos-Esquivel, Isaac Ramírez-Jiménez, Álvaro Víquez-Jaikel · 2024 · Cureus
Abemaciclib and Letrozole in Metastatic Male Breast Cancer
Leon Jonas Schönfeld, Christian Möhring, Rouven Strobel, Hanns Leonhard Kaatsch, Stephan S. Waldeck, Ulrike Wagner · 2024 · Cancer Reports
Fulvestrant Monotherapy After CDK4/6 Inhibitors in Metastatic Breast Cancer Patients: A Real-Life Experience
Margherita Agostini, Anna Mandrioli, Claudio Zamagni · 2024 · Cancers
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
Paola Zagami, Angela Espósito, Beatrice Taurelli Salimbeni, Pier Paolo Maria Berton Giachetti, Roberta Scafetta, Matteo Lambertini, Massimo Di Maïo, Giuseppe Curigliano, Carmen Criscitiello, Saverio Cinieri · 2025 · The Breast
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
Angela M. DeMichele, Amylou Constance Dueck, Dominik Hlauschek, Miguel Martı́n, Harold J. Burstein, GH Pfeiler, Nicholas Zdenkowski, Antonio C. Wolff, Meritxell Bellet, Eric P. Winer et al. · 2025 · Breast Cancer Research
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib
Sylvain Ladoire, Ariane Mamguem Kamga, Loïck Galland, Manon Réda, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhaï, Silvia Mihaela Ilie, Audrey Hennequin, Henri Talucier et al. · 2025 · npj Breast Cancer
Metastatic Breast Cancer Prevalence in New South Wales, Australia, in 2016: A Health Record Linkage Study
Andrea Lynn Smith, Xue Qin Yu, Dianne L. O’Connell, Nehmat Houssami, Belinda Emma Kiely, Anne Elizabeth Cust, David P. Smith, Michael David, Sarah J. Lord · 2025 · Asia-Pacific Journal of Clinical Oncology
Rechallenge of an alternative CDK 4/6 inhibitor after hepatotoxicity in the treatment of hormone-positive metastatic breast cancer
Kasey Jackson, Kiera Roubal, Christopher Andrew Rangel, Frank Brescia · 2025 · Journal of Oncology Pharmacy Practice
Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)
Anne F. de Groot, Danielle Cohen, Joan Barbara Heijns et al. · 2025 · Clinical Cancer Research
Long-term survival outcomes and subtype variations between primary breast cancer and liver metastases in 542 patients with advanced breast cancer: insights from a real-world analysis
Ying Yan, Xinyu Gui, Lijun Di, Hanfang Jiang, Xu Liang, Bin Shao, Guohong Song, Huiping Li · 2025 · Discover Oncology
Position paper on CDK4/6 inhibitors in early breast cancer
Michael Gnant, Christian Fridolin Singer, Gabriel Rinnerthaler, Georg Pfeiler, Daniel Egle, Marija Balić, Rupert Bartsch · 2023 · memo - Magazine of European Medical Oncology
Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole
Masato Takahashi, Tomofumi Osako, Hiroyuki Yasojima, Kenichi Inoue, Masahiro Kawashima, Hideki Maeda, Akemi Ichikawa, Yasuaki Muramatsu, Norikazu Masuda · 2023 · Breast Cancer
Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapy
David O’Reilly, Abdul Rehman Farooq, Paul Nevins Selvadurai, Laura Sheehan, Karen Molan, Bindu Krishnanivas, Valerie Mullen, David John McMahon, Danial Khan Hadi, Ahmed Ahmed et al. · 2024 · The Oncologist
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
Kamilla Fjermeros, Salim Ghannoum, Stephanie Beate Geisler, Sameer Bhargava, Andliena Tahiri, Jovana Klajic, Torben Lüders, Marie Fongaard, Meh Sameen Nawaz, Tatjana Bosnjak et al. · 2024 · Future Oncology
The Clinical Features and Outcomes of Pseudocirrhosis in Breast Cancer
Edward Phillips, Mantegh Sethi, Surammiya Vasanthakumar · 2024 · Cancers
Current and Novel Treatment Options in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Nerea Lopetegui‐Lia, Revati Varma, Jame Abraham, Erin Elizabeth Roesch · 2024 · JCO Oncology Practice
Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies
Prarthna V Bhardwaj, Yara George Abdou · 2024 · Journal of Clinical Oncology
Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer – A Clinical Review
C. Benvenuti, Thomas Grinda, Elie Rassy, Julia R Dixon-Douglas, Joana Mourato Ribeiro, Alberto Zambelli, Armando Santoro, Barbara Pistilli · 2024 · Current Treatment Options in Oncology
Reassessing estrogen receptor expression thresholds for breast cancer prognosis in HER2-negative patients using shape restricted modeling
Wenli Dong, Takeo Fujii, Jing Ning, Toshiaki Iwase, Jing Qin, Naoto Tada Ueno, Yu Shen · 2025 · Scientific Reports
A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System
Jiayan Xu, Ruo Wang, Kunwei Shen · 2025 · Therapeutic Advances in Drug Safety
Pharmacological modulation of cellular senescence: Implications for breast cancer progression and therapeutic strategies
Jialing Xie, Xianlong Shu, Zilan Xie, Jie Tang, Wang Guo · 2025 · European Journal of Pharmacology
Novel Estrogen Receptor – Targeted Therapies in Hormone-Receptor Positive Breast Cancer
Nina E. Neill, Lauren Ann Mauro, Angela Pennisi · 2025 · Current Treatment Options in Oncology
Vitiligo-Like Depigmentation Induced by Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Metastatic Breast Cancer: A Case Report and Literature Review
Chuan Yaw Lee, Lydia Tang-Lin, Sok Yuen Beh · 2025 · Cureus
How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?
Peeter Karihtala · 2025 · Acta Oncologica
Synergistic potential of CDK4 /6 inhibitors and ATRA in non‐ APL AML
Rafał Skopek, Setenay Gupse Özcan, Paulina Chmiel, Stephanie Morgner, Jaqueline Schütt, Faezeh Ghazvini Zadegan, Clara Stanko, Małgorzata Palusińska, Karolina Maślińska-Gromadka, Yordan Sbirkov et al. · 2025 · British Journal of Haematology
Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research
Andrea Nicolini, Paola Ferrari, Roberto Silvestri, Dario A. Bini · 2025 · MedComm
Patient-Reported Outcome Measures to Improve the Care Continuum for Patients With Metastatic Breast Cancer: Opportunities and Implications for Nursing Practice
Kelly M. de Ligt, Belle Hadewijch de Rooij, Linetta B. Koppert, Lonneke Veronique van de Poll-Franse, Galina Velikova, Fátima Cardoso · 2023 · Seminars in Oncology Nursing
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial
Dae‐Won Lee, Kyung Hae Jung, Kyung-Hun Lee et al. · 2023 · European Journal of Cancer
A genome-wide CRISPR/Cas9 knockout screen identifies SEMA3F gene for resistance to cyclin-dependent kinase 4 and 6 inhibitors in breast cancer
Yuko Kawai, Aiko Nagayama, Kazuhiro Miyao, Makoto Takeuchi, Takamichi Yokoe, Tomoe Kameyama, Xinyue Wang, Tomoko Seki, Maiko Takahashi, Tetsu Hayashida et al. · 2024 · Breast Cancer
WITHDRAWN: Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups
Nicky Zhun Hong Wong, Dominic Wei Ting Yap, Rebecca Jia Min Ong, Joseph Jonathan Zhao, Y.H. Chan, Jeremy Chee Seong Tey, Raghav Sundar, J.S.J. Lim, Shaheenah S. Dawood · 2023 · Annals of Oncology · Retracted
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer
Jessica Armand, Sungsoo Kim, Kibum Kim, Eugene Son, Minah Kim, Kevin M. Kalinsky, Hee Won Yang · 2025 · eLife
Modified cachexia index and survival in metastatic breast cancer patients treated with CDK 4–6 inhibitors
Onur Baş, Mert Tokatlı, Mehmet Şavklıyıldız · 2025 · Expert Review of Anticancer Therapy
Impact of Patient Profile on CDK4/6 Inhibitor Therapy Outcomes: A Real-World Data Analysis
Ioana-Miruna Stanciu, Maria Cristina Orlov-Slavu, Andreea Ioana Paroșanu, Cornelia Niţipir · 2025 · International Journal of Molecular Sciences
Dynamic Shielding of Arsenic‐loaded Transferrin with Calcium Manganese Carbonate Potentiates Antitumor Effects via Self‐enhanced Synergistic Therapy
Xiaoyang Gao, Zhaowei Li, Yanwei Zhang · 2025 · Small Methods
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer
Sarah Alexandrou, Christine S. Lee, Kristine J. Fernandez, Celine E Wiharja, Leila Eshraghi, John Reeves, Daniel A. Reed, Neil Portman, Zoe Phan, Heloisa Helena Milioli et al. · 2025 · Journal of Experimental & Clinical Cancer Research
Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitors in Preclinical Adult-Type Ovarian Granulosa Cell Tumor Models
Allison L. Brodsky, Thomas Welte, Veena Kumari Vuttaradhi, Xue Yang, Elio Tahan, Eleonora Khlebus, Joseph Celestino, Reid Trenton Powell, CLIFFORD C. STEPHAN, Nghi H. Nguyen et al. · 2025 · Gynecologic Oncology
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort
Romain Varnier, David Pérol, William Jacot, Audrey Mailliez, Veronique C Dieras, Florence Dalenc, Anthony Gonçalvès, Christelle Lévy, Mónica Arnedos, Jean‐Sébastien Frenel et al. · 2025 · ESMO Open
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer
Richard S. Finn, Hope S. Rugo, Javier Cortés, Sibylle Loibl, Grace Foley, Eric Gauthier, Yao Wang, Sindy Kim, Lars Anders, Dennis J. Slamon · 2025 · Targeted Oncology
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Noor Wortelboer, Seamus Kent, Inge R. H. M. Konings, Annemiek van Ommen‐Nijhof, Vincent van der Noort, Esther van den Pol, Cristina Guerrero Páez, Marlies L. van Bekkum, Franchette W.P.J. van den Berkmortel, Helga J. Droogendijk et al. · 2025 · European Journal of Cancer
Borderline decisions in brain-metastatic breast cancer: efficacy of multimodality treatments in breast cancer patients with very limited prognosis suffering from brain metastases
Stephanie Bendrich, Marc Alexander Wilhelm Pietrkiewicz, Markus Schirmer et al. · 2025 · Clinical & Experimental Metastasis
Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study
Thiti Susiriwatananont, Concord Wongkraisri, Thanate Dajsakdipon, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Suthinee Ithimakin, Thitiya Sirisinha Dejthevaporn, Napa Parinyanitikul et al. · 2025 · International Journal of Breast Cancer
Real-World Clinical Experience of First-Line Ribociclib Combined with an Aromatase Inhibitor in Metastatic Breast Cancer
Ana S. Cvetanović, Kristina B. Jankovic, Ana S. Stojković, Nikola Živković, Miloš S. Kostić, LAZAR S. POPOVIC · 2026 · Cancers
Neoadjuvant therapy and translational biomarkers for metastatic risk in early breast cancer
Anna McCracken, Olivia R. Grafinger, Hon Sing Leong, Ana Elisa Lohmann, Katarzyna Joanna Jerzak, Sunit Das · 2026 · Cancer Treatment Reviews
Prediction of dose reductions and impact of reduced starting doses of CDK4 /6i on effectiveness in HR ‐positive/ HER2 ‐negative metastatic breast cancer: Real‐world data from the OPAL registry
Patrick Marschner, Kai G. Ringwald, Marc Thill, Mark‐Oliver Zahn, Anja Welt, Arnd Nusch, Gabriele Kaltenecker, Yolanda Rodemer, Volker A. Hagen, Caroline Schock et al. · 2026 · International Journal of Cancer
Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies
Harold N. Tan, Giuseppe Curigliano, Timothy Anthony Yap · 2026 · Trends in cancer
Precision targeted therapy and immunotherapy in breast cancer: Advances and clinical frontiers
W Y Song, Pangzhou Chen, Wen Zhou, H T Wang, Cailu Song, Zhi Tian, Ziyun Guan, Hailin Tang · 2026 · Chinese Medical Journal
Inhibiting cyclin D1–CDK6 suppresses senescence-associated inflammatory gene expression and age-related functional decline
Adarsh Rajesh, Aaron P. Havas, Rouven Arnold, Kathryn Lande, Xue Lei, Kelly Yichen Li, Armin Gandhi, Ana Catarina Franco, Seung‐Hwa Woo, Anthony B. Lagnado et al. · 2026 · Nature Aging
Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
Alberto D’Angelo, Fabiola Giudici, Robert Chapman, Jacob Darlow, Huseyin Kilili, Navid Sobhani, Mattia Cinelli, Maria Rosa Cappelletti, Carla Strina, Manuela Milani et al. · 2022 · Current Issues in Molecular Biology
Experimental and clinical evidence in favour of an effective immune stimulation in ER-positive, endocrine-dependent metastatic breast cancer
Andrea Nicolini, Giuseppe Rossi, Paola Ferrari · 2024 · Frontiers in Immunology
First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution
Guillermo Valencia, Patricia Rioja, Miguel Chirito, Olenka Peralta, Jorge Sánchez, Connie Rabanal, Raúl Mantilla, Zaida Morante, Hugo Alejandro Fuentes, Carlos Castaneda et al. · 2024 · Current Oncology
Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2− breast cancer
Shadab A. Rahman, Hanneke Poort, Deborah Schrag, Stephanie C. Tung, Eric S. Zhou, Aleta Wiley, Lauren B. Finkelstein, Elkhansaa Elguenaoui, Moira Nolan, Erica L. Mayer et al. · 2024 · The Oncologist
Large Unstained Cells (LUC): A Novel Predictor of CDK4/6 Inhibitor Outcomes in HR+ HER2-Negative Metastatic Breast Cancer
Furkan Ceylan, Mirmehdi Mehdiyev, Didem Şener Dede, Safa Can Efil, Ateş Kutay Tenekeci, Burak Bi̇lgi̇n, Şebnem Yücel, Hayriye Tatlı Doğan, Mehmet Alı Nahıt Şendur, Muhammed Bülent Akıncı et al. · 2024 · Journal of Clinical Medicine
Comparative analysis of CDKI-related adverse events in older patients: a real-world data from the FDA adverse event reporting system database
Qiongtong Fang, Fuqiang Huang, Huibin Zhao, Jiabi Liang, Yishen Chen, Xinrong Wu, Meirong Zhang, Wenji Luo · 2025 · Expert Opinion on Drug Safety
CDK4/6 Inhibitors in Patients with Breast Cancer: A Review of Adverse Event Profiles and Recommendations for Supportive Care Interventions
Kathryn Elizabeth Post, Mia Holtze, Steven Jay Isakoff, Leif William Ellisen, Jamie M. Jacobs, Seth Andrew Wander, Joseph Andrew Greer · 2025 · Current Breast Cancer Reports
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor–positive breast cancer
Connie Lau, Krista LaBorde, Bilqees Fatima, Shahad S Alfartosy, Susan Abughosh, Rodrigo M De La Torre, Erika N. Brown, Meghana V. Trivedi · 2025 · Breast Cancer Research and Treatment
Physicians’ knowledge, practice, and attitudes on fertility and pregnancy-related issues in young women with advanced breast cancer: results of the ABC6 and ABC7 survey
Simone Nardin, Luca Arecco, Virginia Delucchi, Eva Blondeaux, Mihaela Stana, Luciana de Moura Leite, Luiza Nardin Weis, Giang Pham Hoang, Arianna Daneri, Francesca Bruzzone et al. · 2025 · The Breast
Beyond Conventional Approaches: The Revolutionary Role of Nanoparticles in Breast Cancer
Mohan Liu, Yusi Wang, Yan Li, Yibing Zhang, Bailing Zhou, Lei Yang, Xi Yan, Li Yang · 2025 · MedComm – Biomaterials and Applications
Tumour Cell Size Control and Its Impact on Tumour Cell Function
Min Zhou, Mei Ling Zhou, Yang Jin · 2025 · Cell Proliferation
In Defense of Adjuvant CDK4/6 Inhibitors in Early Breast Cancer
Michelino De Laurentiis, Roberto Buonaiuto, Giuseppe Buono · 2025 · Journal of Clinical Oncology
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study
Michelino De Laurentiis, Roberta Caputo, Manuelita Mazza, Mauro Mansutti, Riccardo Masetti, Z. Ballatore, Rosalba Torrisi, Andrea Michelotti, Alberto Zambelli, Antonella Ferro et al. · 2022 · Targeted Oncology
Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations
Sarah Sharman Moser, Orr Friedman Mazursky, Hadas Shalev · 2023 · Future Oncology
Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer
Junghoon Shin, Ji‐Yeon Kim, Jung Min Oh, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Won Park, Yeon Hee Park, Jin Seok Ahn, Young‐Hyuck Im · 2023 · Cancers
An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
Mainak Bardhan, Debankur Dey, Vinay Suresh, Binish Javed, Vyshak Alva Venur, Neha Joe, Ritvika Kalidindi, Ahmad Ozair, Marium Khan, Reshma L Mahtani et al. · 2023 · Expert Review of Neurotherapeutics
Updates in the treatment of HR+HER2- breast cancer
Nikita Vashi Baclig, Kelly Elizabeth McCann · 2023 · Current Opinion in Obstetrics & Gynecology
Role of Cyclin-Dependent Kinase 4/6 in Metastatic Breast Cancer: Real-World Data From a Tertiary Care Institute in Eastern India
Saroj Kumar Das Majumdar, Sandip Kumar Barik, Ashutosh Pattanaik, Deepak Kumar Das, Dillip Kumar Parida · 2024 · Cureus
Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?
Valentina Magri, Luca Marino, Gianluigi De Renzi · 2024 · Biomedicines
Emerging drugs in breast cancer: a focus on antibody–drug conjugates and novel treatment options in luminal disease
Rupert Bartsch · 2024 · memo - Magazine of European Medical Oncology
What are the needs in oral antitumor therapy? An analysis of patients’ and practitioners’ preferences
Anna Hester, Franziska Henze, Anna Marie Debes, Charlotte Leonie Schubert, Alexander Koenig, Nadia Harbeck, Rachel Wuerstlein · 2024 · Frontiers in Oncology
Confirming the efficacy and safety of CDK4/6 inhibitors in the first-line treatment of HR+ advanced breast cancer: a systematic review and meta-analysis
Xin Guan, Mengyuan Li, Xingyue Ji, Yufei Wang, Lei Tian · 2024 · Frontiers in Pharmacology
Effect of Cyclin-Dependent Kinase 4/6 Inhibitors on Circulating Cells in Patients with Metastatic Breast Cancer
Soraia Lobo-Martins, Patrícia Corredeira, Ana C. Martins Cavaco, Carolina Rodrigues, Paulina Piairo, Cláudia Lopes, Joana S. Fraga, Madalena Pereira da Silva, Patrícia Alves, Lisiana Wachholz Szeneszi et al. · 2024 · Cells
Local Control of Advanced Breast Cancer—Debate in Multidisciplinary Tumor Board
Iuliana Pantelimon, Andra Maria Stancu, Simona Coniac, Andreea-Iuliana Ionescu, Dimitrie-Ionuț Atasiei, Dragos Eugen Georgescu, Laurentia Nicoleta Gales · 2025 · Journal of Clinical Medicine
First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eligible population
Lucille Sun, David Leroy Veenstra, Adam Brufsky, Timothy Pluard, Rickard Sandin, Stella Stergiopoulos, Xianchen Liu, Troy Williams, Sean D. Sullivan · 2025 · Journal of Managed Care & Specialty Pharmacy
Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group
İzzet Doğan, Sercan Aksoy, Burcu Çakar, Gül Başaran, Özlem Erçelep, Nil Molinas Mandel, Taner Korkmaz, Erhan Gökmen, Bedrettin Cem Sener, Adnan Aydıner et al. · 2023 · Cancers
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer
Jessica Armand, Sungsoo Kim, Kibum Kim, Eugene Son, Minah Kim, Kevin M. Kalinsky, Hee Won Yang · 2025 · eLife
Clinicopathological features, treatment patterns, and survival outcomes among Syrian patients with advanced breast cancer
Muhammad Muhammad, Mousa Alali, Maher Saifo · 2024 · Frontiers in Oncology
Exploring the Potential of Adjuvant CDK4/6 Inhibitors in Hormone Receptor-Positive Early Breast Cancer: A Consistent Approach for All
Jianbin Li · 2025 · Cancers
Valuable predictive power of prognostic nutritional index in metastatic breast cancer patients treated with CDK4/6 inhibitors
Tuğba Önder, İrem Öner, Cengiz Karaçin · 2025 · Japanese Journal of Clinical Oncology
Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR +/ HER2 − Metastatic Breast Cancer
Adam Brufsky, Rickard Sandin, Stella Stergiopoulos, Connie Chen, Siddharth S. Karanth, Benjamin C. Li, Elizabeth J. Esterberg, Doris Makari, Sean D. Candrilli, RK Goyal et al. · 2025 · Cancer Medicine
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study
Thomas W. Decker, Cosima V. M. Brucker, Anne Engel, Peter Andreas Fasching, Thomas Göhler, Christian Jackisch, Jan Janßen, A. Köhler, Kerstin Lüdtke-Heckenkamp, Diana Lüftner et al. · 2025 · ESMO Open
Updated efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in elderly women with HR+/HER-2 metastatic or advanced breast cancer: patient-level network meta-analysis
Henry W. C. Leung, M. Tsai, Shin-Hang Leung, Shyh-Yau Wang, Agnes L. F. Chan · 2025 · Aging
A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018)
Fernanda Damian, Andréia Cristina de Melo, Graziela Zibetti Dal Molin, Angélica Nogueira‐Rodrigues, Aknar Calabrich, Gustavo Werutsky, Elias Abdo Filho, Taiane Francieli Rebelatto, Rafaela Gomes de Jesus, Mirela Foresti Jiménez · 2025 · Gynecologic Oncology
Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review
Zhi‐Min Chen, Peng Xie, Qihai Chen, Jie Ouyang · 2025 · Breast Cancer Targets and Therapy